The “Antidementia Drugs” are not discussed in the chapter “Psychotropic Drugs” of the Drug Prescription Report 2012 (see my posts from November 9th, 2012, from December 16th, 2012 and from January 19th, 2013), but in a separate chapter. This chapter was not written by Martin Lohse and Bruno Müller-Oerlinghausen but Ulrich Schwabe, one of the two editors of the Drug Prescription Report. Different from the chapter “Psychotropic Drugs”, the chapter on “Antidementia Drugs” is written objectively and scientifically throughout.
Prescription of antidementia drugs has changed considerably in the last decade in Germany.
Today I want to once again report from the 51st Congress of the American College of Neuropsychopharmacology (ACNP), 2nd – 6th December 2012 in Hollywood, Florida, even though the Congress has already ended. The study was presented as a poster, but I believe it could have been also presented in the “Highlights” session, in which unfortunately the preclinical work dominated (see my last posting dated 12/04/2012).
At least in Germany, acetylcholinesterase inhibitors still have the reputation of being of dubious benefit in patients with dementia of the Alzheimer’s type. It is widely believed that their effect is limited and is in no way proportionate to the adverse effects and costs.